$APRE
Aprea Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000155837023018572 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $14.08K $320.0K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.643M $1.720M $3.083M
YoY Change -22.49% -44.2% -9.73%
% of Gross Profit
Research & Development $2.046M $2.123M $1.118M
YoY Change 284.96% 89.93% -81.42%
% of Gross Profit
Depreciation & Amortization $7.050K $0.00 $120.00
YoY Change -394.98% -100.0% -96.18%
% of Gross Profit
Operating Expenses $3.689M $3.842M $4.200M
YoY Change 39.12% -8.52% -55.46%
Operating Profit -$3.523M -$4.200M
YoY Change -16.13%
Interest Expense $231.7K $321.2K $151.1K
YoY Change 10.59% 112.55% -458048.48%
% of Operating Profit
Other Income/Expense, Net $318.3K $175.5K
YoY Change 81.41% -899.8%
Pretax Income -$3.443M -$3.200M -$4.025M
YoY Change 40.99% -20.49% -57.42%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.443M -$3.205M -$4.025M
YoY Change 40.99% -20.38% -57.42%
Net Earnings / Revenue -24454.9% -1001.41%
Basic Earnings Per Share -$0.86 -$0.12
Diluted Earnings Per Share -$0.92 -$0.85 -$0.12
COMMON SHARES
Basic Shares Outstanding 3.737M 3.737M 23.40M
Diluted Shares Outstanding 3.732M 34.66M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.61M $25.40M $33.11M
YoY Change -24.94% -23.29% -46.1%
Cash & Equivalents $21.61M $25.40M $33.11M
Short-Term Investments
Other Short-Term Assets $914.3K $300.0K $361.2K
YoY Change -33.11% -16.94% -51.9%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $22.52M $25.64M $33.47M
YoY Change -25.31% -23.4% -46.17%
LONG-TERM ASSETS
Property, Plant & Equipment $88.36K $86.20K $12.24K
YoY Change 3706.98% 604.4% -55.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $40.72K $0.00 $29.35K
YoY Change -100.0% -0.08%
Total Long-Term Assets $129.1K $126.6K $148.1K
YoY Change 5460.97% -14.5% -51.52%
TOTAL ASSETS
Total Short-Term Assets $22.52M $25.64M $33.47M
Total Long-Term Assets $129.1K $126.6K $148.1K
Total Assets $22.65M $25.77M $33.62M
YoY Change -24.89% -23.36% -46.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.670M $862.6K $1.136M
YoY Change 98.2% -24.08% -55.42%
Accrued Expenses $2.186M $3.300M $2.862M
YoY Change -7.3% 15.3% -55.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.386M $4.166M $3.998M
YoY Change 37.0% 4.2% -55.77%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.386M $4.166M $3.998M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $4.386M $4.200M $3.998M
YoY Change 37.0% 5.05% -55.92%
SHAREHOLDERS EQUITY
Retained Earnings -$308.1M -$304.6M -$291.4M
YoY Change 4.86% 4.56% 68.04%
Common Stock $3.736K $3.736K $52.24K
YoY Change 40.72% -92.85% 144.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.26M $20.29M $26.63M
YoY Change
Total Liabilities & Shareholders Equity $22.65M $25.77M $33.62M
YoY Change -24.89% -23.36% -46.19%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$3.443M -$3.205M -$4.025M
YoY Change 40.99% -20.38% -57.42%
Depreciation, Depletion And Amortization $7.050K $0.00 $120.00
YoY Change -394.98% -100.0% -96.18%
Cash From Operating Activities -$3.738M -$2.240M -$6.593M
YoY Change -7.04% -66.02% -19.93%
INVESTING ACTIVITIES
Capital Expenditures $3.090K $90.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$3.090K -$90.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00 0.000 584.5K
YoY Change -100.01% -100.0% 572.01%
NET CHANGE
Cash From Operating Activities -3.738M -2.240M -6.593M
Cash From Investing Activities -3.090K -90.00K 0.000
Cash From Financing Activities -10.00 0.000 584.5K
Net Change In Cash -3.741M -2.330M -6.008M
YoY Change -4.62% -61.22% -26.25%
FREE CASH FLOW
Cash From Operating Activities -$3.738M -$2.240M -$6.593M
Capital Expenditures $3.090K $90.00K $0.00
Free Cash Flow -$3.741M -$2.330M -$6.593M
YoY Change -6.96% -64.66% -19.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-83.33
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3731571
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1732783
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3576268
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1322652
dei Entity Central Index Key
EntityCentralIndexKey
0001781983
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3736673
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2655269
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39069
dei Entity Registrant Name
EntityRegistrantName
Aprea Therapeutics, Inc.
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-293796405
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-2246769
dei Entity Address Address Line1
EntityAddressAddressLine1
3805 Old Easton Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Doylestown
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
18902
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
463-9385
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
APRE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3736673
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25353513
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28786647
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
286263
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1366859
CY2023Q3 us-gaap Assets Current
AssetsCurrent
25639776
CY2022Q4 us-gaap Assets Current
AssetsCurrent
30153506
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
86198
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2321
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
40449
CY2023Q3 us-gaap Assets
Assets
25766423
CY2022Q4 us-gaap Assets
Assets
30155827
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
862552
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
842754
CY2023Q3 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
3303510
CY2022Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2358332
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4166062
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3201086
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3736673
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2655269
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
3736
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2655
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
335561343
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
330060836
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10635874
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10623408
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-304639907
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
20289298
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
25643678
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25766423
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30155827
CY2023Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
319468
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
569156
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2122603
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1117576
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5581802
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
15870867
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1719715
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3082618
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6784388
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18849549
apre Acquired Research And Development In Process
AcquiredResearchAndDevelopmentInProcess
76020184
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3842318
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
4200194
us-gaap Operating Expenses
OperatingExpenses
12366190
us-gaap Operating Expenses
OperatingExpenses
110740600
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3522850
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4200194
us-gaap Operating Income Loss
OperatingIncomeLoss
-11797034
us-gaap Operating Income Loss
OperatingIncomeLoss
-110740600
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
321215
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
151123
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
913846
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
205585
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2880
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
24353
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
39686
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
315130
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
318335
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
175476
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
953532
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
520715
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3204515
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4024718
us-gaap Net Income Loss
NetIncomeLoss
-10843502
us-gaap Net Income Loss
NetIncomeLoss
-110219885
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1002
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
26161
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12466
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
118311
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3205517
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3998557
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10855968
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-110101574
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.86
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-83.33
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3735176
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1732783
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3577482
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1322652
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
49506964
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2084060
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-65505
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7936693
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
43588826
CY2022Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
1329699
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2602850
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14801615
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
157655
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-98258474
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-35777829
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
584447
CY2022Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
65778931
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
38236
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
26161
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4024718
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
26625228
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
25643678
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4871865
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16244
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
61956
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4379890
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
26481978
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
269323
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-73420
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3259097
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
23418784
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
76031
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1002
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3204515
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
20289298
us-gaap Profit Loss
ProfitLoss
-10843502
us-gaap Profit Loss
ProfitLoss
-110219885
apre Research And Development In Process Noncash
ResearchAndDevelopmentInProcessNoncash
72523293
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2066
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6788
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
361598
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
16923911
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
182042
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
39686
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
315130
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1077138
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3166506
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
21873
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-565203
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
982563
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2510258
apre Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-182688
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8437950
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20990624
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
85943
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-85943
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5788918
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
584447
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
648928
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5139990
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
584447
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3383903
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-20406177
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-8782
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
442726
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28786647
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53076052
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25393962
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33112601
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25353513
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33112601
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
40449
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25393962
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33112601
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
113612
us-gaap Stock Issued1
StockIssued1
70107167
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25400000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
77022
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b>—The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions, are used for, but not limited to, include stock-based compensation and accounting for research and development costs.</p>
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
40000
us-gaap Operating Lease Expense
OperatingLeaseExpense
59993
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
634623
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
621660
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
19998
us-gaap Operating Lease Expense
OperatingLeaseExpense
236738
apre Lessee Operating Lease Annual Base Rent
LesseeOperatingLeaseAnnualBaseRent
101000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
61248
us-gaap Operating Lease Cost
OperatingLeaseCost
182042
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
64056
us-gaap Operating Lease Payments
OperatingLeasePayments
192169
us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
123786
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
194946
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
75012
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1040804
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1397977
CY2023Q3 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
1914990
CY2022Q4 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
688858
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
152770
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
196485
CY2023Q3 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
3303510
CY2022Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2358332
CY2023Q3 apre Stock Shares Authorized
StockSharesAuthorized
440000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
apre Common Stock Number Of Voting Rights Per Share
CommonStockNumberOfVotingRightsPerShare
1
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
76031
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
38236
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
361598
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16900000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
100000
CY2022Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
100000
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0

Files In Submission

Name View Source Status
apre-20230930_cal.xml Edgar Link unprocessable
0001558370-23-018572-index-headers.html Edgar Link pending
0001558370-23-018572-index.html Edgar Link pending
0001558370-23-018572.txt Edgar Link pending
0001558370-23-018572-xbrl.zip Edgar Link pending
apre-20230930.xsd Edgar Link pending
apre-20230930x10q.htm Edgar Link pending
apre-20230930xex31d1.htm Edgar Link pending
apre-20230930xex31d2.htm Edgar Link pending
apre-20230930xex32d1.htm Edgar Link pending
apre-20230930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
apre-20230930_def.xml Edgar Link unprocessable
apre-20230930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
apre-20230930_pre.xml Edgar Link unprocessable
apre-20230930x10q_htm.xml Edgar Link completed